Positron Emission Tomography Tracers for Synucleinopathies
Author Information
Author(s): Xiang Jie, Zhang Zhentao, Wu Shengxi
Hypothesis
Molecular imaging is crucial for differentiating synucleinopathies and assessing drug efficacy.
Conclusion
Recent advances in molecular imaging have led to the development of promising α-synuclein-specific tracers for PET, although challenges remain.
Supporting Evidence
- Approximately 7 to 10 million people worldwide are affected by Parkinson's disease.
- Imaging α-Syn is important for monitoring disease progression and early diagnosis.
- α-Syn aggregates can be essential biomarkers for detecting Parkinson's disease and other synucleinopathies.
Takeaway
This study talks about how scientists are trying to create special tools to see a brain problem called synucleinopathies, which includes diseases like Parkinson's.
Methodology
The review summarizes recent findings on PET tracers targeting α-synuclein and discusses their characteristics and development challenges.
Limitations
The study highlights the ongoing challenges in developing effective α-synuclein PET tracers due to low aggregate concentrations and structural diversity.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website